The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
- Sponsor
- Tina Vilsbøll
- Study ID
- NCT06606821
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Atherosclerosis Cardiovascular Disease
- Chronic Coronary Artery Disease
- Coronary Artery Disease
- Coronary Microvascular Dysfunction
- Overweight or Obesity
- Stable Angina Pectoris
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tirzepatide — DRUGInvestigational drug will be administered as a sc. injection once-weekly.
- Placebo — DRUGPlacebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
Study Details
The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.
Key Dates
- Start date
- Oct 1, 2024
- Status verified
- May 2025
- Primary completion
- Mar 20, 2027
- Completion
- Aug 1, 2028
Study Design
- Enrollment
- 124 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: TirzepatideTirzepatide is administered sc. once-weekly.
- Placebo Comparator: PlaceboPlacebo is administered sc. once-weekly.
Primary Outcome Measure
Lipid core burden index [ Time Frame: Between-group difference in change from baseline to week 52 in participants treated with tirzepatide vs placebo: ]
Central Contacts
- Daniel Raaschou-Oddershede, MD+4520157448
- Christine Rode Schwarz, MD, PhD
Related Studies
- Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem CellsEnrolling By Invitation · Scripps Translational Science Institute · La Jolla, California
- Product Surveillance RegistryRecruiting · Medtronic · Birmingham, Alabama
- Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)PHASE2 · Not Yet Recruiting · Cell>Point LLC · Oklahoma City, Oklahoma
- Factors Affect Outcomes in Cardiovascular SurgeryRecruiting · University of California, Davis · Sacramento, California